• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

GLP-1 Patients Missed Over $10M in Potential Savings in a Single Quarter, Report Finds

by Jasmine Pennic 06/23/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– A new data analysis from DoseSpot, a leader in e-prescribing and healthcare technology solutions, found that 92 percent of GLP-1 prescriptions the company processed in Q1 2025 could have been filled at a lower price. This translates to a staggering $10.2M in missed savings for patients on these popular medications.

– The analysis of over 100,000 prescriptions highlights a significant gap in cost transparency and access to savings programs, contributing to the high cost of these drugs for millions of Americans.

A Widespread Problem with a Simple Solution

The analysis focused on 102,166 prescriptions for manufacturer brands like Mounjaro, Ozempic, and Zepbound. It evaluated whether each prescription was eligible for additional savings through different pharmacies or via manufacturer cost-saving programs.

The findings were clear: the vast majority of patients are overpaying. The potential savings would have come from three key areas:

  1. Giving patients transparent pharmacy pricing information.
  2. Letting patients choose their pharmacy or dispensing option.
  3. Utilizing manufacturer cost-savings programs.

The bulk of the potential savings—a massive $7M—would have come directly from manufacturer cost-savings programs, which many patients are simply unaware of.

The High Cost of Non-Adherence

With 1 in 8 American adults having reported using a GLP-1, and cost being the top reason why 33% of Americans don’t fill their prescriptions, these missed savings have a direct impact on medication adherence and health outcomes. Out-of-pocket drug spending is on the rise, increasing by 25% over the last five years to $98 billion in 2024.

GLP-1 medication adherence is particularly low, with just 46.3% of users still on the medication after 180 days. Savings programs are a critical component to improving adherence, not just for one-time use but on a recurring basis.

“Regardless of their insurance status, the vast majority of patients are still unaware of cost saving programs,” said Josh Weiner, CEO of DoseSpot. “Patients need to do their homework – a quick online search for these programs can yield significant savings. Patients also need to speak with providers about pharmacy pricing and dispensing options – providers can access these details, but most don’t share it proactively – you need to ask.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: GLP-1

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |